TABLE 1

Demographics, Treatment, and Imaging Details

Baseline characteristicData
No. of patients that underwent 166Ho radioembolization15
Sex
 Male9
 Female6
Age (y)55 (38–87)
Tumor type (primary)
 Ocular melanoma6
 Colorectal carcinoma6
 Cholangiocarcinoma2
 Breast carcinoma1
Tumor vascularity
 Hypervascular3
 Hypovascular10
 Centrally hypovascular and peripherally hypervascular2
Liver tumor involvement
 Absolute fraction14% (2%–52%)
 0%–25%10
 25%–50%4
 >50%1
No. of tumors per patient5 (1–21)
Desired whole-liver absorbed dose
 20 Gy6
 40 Gy3
 60 Gy3
 80 Gy3
Bilobar treatment (whole-liver treatment in one session)
 Injection from proper or common hepatic artery7
 Sequential injection from left and right hepatic arteries5
Lobar treatment*
 Injection from right hepatic artery2
 Injection from left hepatic artery1
Net administered amount of microspheres (mg)484 ± 53
Net administered 166Ho activity (MBq)5,085 ± 2,876
Whole-liver absorbed dose (Gy)†40 ± 23
Quantitative imaging
 Eligible for SPECT dosimetry
  Yes15
  No0
 Eligible for MR imaging dosimetry
  Yes9
  No6 (claustrophobia, n = 1; metal clips, n = 5)

  • ↵* Unilobar treatment because of unilateral disease (n = 1) or previous hemihepatectomy (n = 2).

  • ↵† Assuming all energy of net administered activity was absorbed in liver.

  • Data are number, median followed by range in parentheses, or mean followed by SD.